Dabigatran - A case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Frontiers in Pharmacology

Volumn 4 MAY, Issue , 2013, Pages

  Malmström, Rickard E ^a   Godman, Brian B ^a,b,c   Diogene, Eduard ^d   Baumgärte, Christoph ^e   Bennie, Marion ^c,f   Bishop, Iain ^f   Brzezinska, Anna ^g   Bucsics, Anna ^h   Campbell, Stephen ⁱ   Ferrario, Alessandra ^j   Finlayson, Alexander E ^k   Fürst, Jurij ^l   Garuoliene, Kristina ^m   Gomes, Miguel ⁿ   Gutiérrez Ibarluzea, Iñaki ^o   Haycox, Alan ^b   Hviding, Krystyna ^p   Herholz, Harald ^q   Hoffmann, Mikael ^r   Jan, Saira ^s   Jones, Jan ^t   Joppi, Roberta ^u   Kalaba, Marija ^v   Kvalheim, Christina ^p   Laius, Ott ^w   Langner, Irene ^x   Lonsdale, Julie ^y   Lööv, Sven Åke ^z   Malinowska, Kamila ^aa,ab   McCullagh, Laura ^ac   Paterson, Ken ^ad   Markovic Pekovic, Vanda ^ae,af   Martin, Andrew ^ag,as   Piessnegger, Jutta ^h   Selke, Gisbert ^w   Sermet, Catherine ^ah   Simoens, Steven ^ai   Tulunay, Cankat ^aj   Tomek, Dominik ^ak,al   Voncina, Luka ^am   Vlahovic Palcevski, Vera ^an   Wale, Janet ^ao   Wilcock, Michael ^ap   Wladysiuk, Magdalena ^aa   Van Woerkom, Menno ^aq   Zara, Corrine ^ar   Gustafsson, Lars L ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d INSTITUT CATALÀ DE LA SALUT   (Spain)

^e Austrian Medicines and Medical Devices Agency   (Austria)

^f INFORMATION SERVICES DIVISION   (United Kingdom)

^g Agency for Health Technology Assessment in Poland   (Poland)

^h Hauptverband der Osterreichischen Sozialversicherungstrager   (Austria)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l Health Insurance Institute   (Slovenia)

^m National Health Insurance Fund   (Lithuania)

ⁿ Inst Nac Farmacia Medicamento   (Portugal)

^o Osteba Basque Office for HTA   (Spain)

^p Norwegian Medicines Agency   (Norway)

^q Kassenärztliche Vereinigung in Hessen KVH   (Germany)

^r LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^s Hlth Serv Partnership Dorchester   (United States)

^t NINEWELLS HOSPITAL   (United Kingdom)

^u Local Health Unit of Verona   (Italy)

^v Republic Institute for Health Insurance   (Serbia)

^w State Agency of Medicines   (Estonia)

^x Wissenschaftliches Institut der AOK   (Germany)

^y Lancashire Commissioning Support Unit   (United Kingdom)

^z STOCKHOLM COUNTY COUNCIL   (Sweden)

^aa HTA CONSULTING   (Poland)

^ab MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^ac ST JAMES S HOSPITAL   (Ireland)

^ad Scottish Medicines Consortium   (United Kingdom)

^ae UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^af MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^ag NHS Bury   (United Kingdom)

^ah Institute de Recherche et Documentation en Économie de la Santé   (France)

^ai UNIVERSITY OF LEUVEN   (Belgium)

^aj President of the Turkish Rational Drug Use Platform   (Turkey)

^ak Physics and Informatics   (Slovakia)

^al SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^am Ministry of Health   (Croatia)

^an KBC RIJEKA   (Croatia)

^ao Independent Consumer Advocate   (Australia)

^ap ROYAL CORNWALL HOSPITALS NHS TRUST   (United Kingdom)

^aq Dutch Institute for Rational Use of Medicine   (Netherlands)

^ar C Agy Hlth Technol Assess Res   (Spain)

^as NHS Greater Manchester Commissioning Support Unit   (United Kingdom)

more..

Author keywords

Critical drug evaluation; Dabigatran; Demand side measures; Drug and therapeutics committees; Managed introduction new medicines; Pharmacovigilance; Registries; Risk sharing

Indexed keywords

DABIGATRAN; NEW DRUG; WARFARIN; ANTICOAGULANT AGENT; NATALIZUMAB; ZIMELDINE;

ARTICLE; CEREBROVASCULAR ACCIDENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DESCRIPTIVE RESEARCH; DRUG COST; DRUG MARKETING; DRUG MONITORING; DRUG UTILIZATION; EUROPE; FUNDING; HEART ATRIUM FIBRILLATION; HUMAN; MODEL; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; AUSTRIA; BLEEDING; BRAIN HEMORRHAGE; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; COST OF ILLNESS; DISABILITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG ELIMINATION; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; EDUCATION; EMBOLISM; FINLAND; FOOD AND DRUG ADMINISTRATION; GERMANY; HEALTH PROMOTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LAW ENFORCEMENT; LEGAL ASPECT; MORTALITY; NONBIOLOGICAL MODEL; ORGANIZATION; PHYSICIAN; PREVALENCE; PUBLICATION; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SLOVENIA; SWEDEN; UNITED KINGDOM;

EID: 84881534674     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00039     Document Type: Article

References (187)

1. Abraham, J. (2008). Sociology of pharmaceuticals development and regulation: a realist empirical research programme. Sociol. Health Illn. 30, 869-885.
2. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osinska, B., Herholz, H., Wendykowska, K., et al. (2010). Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Serv. Res. 10:153. doi: 10.1186/1472-6963-10-153
3. Agencja Oceny Technologii Medycznych Rada Przejrzystosci. (2012). Dabigatran. Available at: http://www.aotm.gov.pl/assets/files/rada/rekomendacje_stanowiska/2012_SRP/R-08-2012-Pradaxa/Stanowisko_RP_AOTM_8_2012_Pradaxa_(dabigatran)_prewencja.pdf (accessed January 2013).
4. Australian Government Department of Health and Ageing. (2012). Review of Anticoagulation Therapies in Atrial Fibrillation. Available at: http://www.pbs.gov.au/reviews/atrial-fibrillation-files/report-anticoagulation.pdf (accessed January 2013).
5. Baetz, B. E., and Spinler, S. A. (2008). Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 28, 1354-1373.
6. Banerjee, A., Lane, D. A., Torp-Pedersen, C., and Lip, G. Y. (2012). Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107, 584-589.
7. Baumgärtel, C., Godman, B., Malmstrom, R. E., Andersen, M., Abuelkhair, M., Abdu, S., et al. (2012). What lessons can be learned from the launch of generic clopidogrel? GaBi J. 1, 58-68.
8. Bennie, M., Godman, B., Bishop, I., and Campbell, S. (2012). Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12, 125-130.
9. Boehringer Ingelheim. (2011a). Breakthrough Therapy PRADAXA® (Dabigatran Etexilate) First Drug in 50 Years to Gain Approval for Stroke Prevention in Atrial Fibrillation in EU. Available at: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/04_aug_2011_dabigatranetexilate.html (accessed December 2012).
10. Boehringer Ingelheim. (2011b). Mitteilung an die Angehörigen der Heilberufe zur Bedeutung einer überprüfung der Nierenfunktion von Patienten, die mit Pradaxa® (Dabigatranetexilat) behandelt warden. Available at: http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2011/20111027.pdf (accessed December 2012).
11. Bombardier, L., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520-1528.
12. Bresalier, R., Sandler, R., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., et al. (2005). Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102.
13. Burke, P. (2012). Communications (by letter) from Mr. P. Burke (Primary Care Reimbursement Services, Health Services Executive, Ireland) to All Chairpersons/Secretaries of Drug and Therapeutic (Pharmacy and Therapeutic) Committees, Consultant (Cardiologists, Geriatricians, Haematologists, Neurologists, Stroke Physicians), Hospital Chief Pharmacists, Ireland, July 2012.
14. Calfee, J. E., and Pinell, X. (2005). Prepared for a Conference on Consumers, Information, and the Evolving Healthcare Market Place. Available at: http://www.aei.org/papers/health/the-significance-of-the-vioxx-withdrawal/ (accessed December 2012).
15. Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., et al. (2010). ESC Guidelines for the management of atrial fibrillation the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2369-2429.
16. Carlson, A. (1999). "The discovery of SSRIs: a milestone in neuropsychopharmacology and rational drug design," in Selective Serotonin Reuptake Inhibitors: Past, Present and Future, ed. S. C. Standford (Austin: R.G. Landes Company), 1-7. Available at: http://elib.fk.uwks.ac.id/asset/archieve/e-book/FISIOLOGI%20-%20FAAL%20-%20PHISIOLOGY%20-%20PATHOFISIOLOGY/Selective%20Serotonin%20Reuptake%20Inhibitors.pdf (accessed January 2013).
17. Carlson, A. (2000). A half century of neurotransmitter research; impact on neurology and psychiatry. Nobel lecture December 2000. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2000/carlsson-lecture.pdf (accessed January 20123)
18. Cheema, P., Gauvra, S., Migus, M., Godman, B., Yeung, L., Trudeau, M. E., et al. (2012). International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr. Oncol. 19, e165-e176.
19. Civaner, M. (2012). Sale strategies of pharmaceutical companies in a 'pharmerging' country: the problems will not improve if the gaps remain. Health Policy 106, 225-232.
20. Coma, A., Zara, C., Godman, B., Augusti, A., Diogene, E., Wettermark, B., et al. (2009). Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9, 569-581.
21. Connolly, S. J., Ezekowitzs, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151.
22. Coventry and Warwickshire Area Prescribing Committee. (2012). Dabigatran (Pradaxa®) in Atrial Fibrillation. Available at: http://www.coventry.nhs.uk/CmsDocuments/f32f3f79-d837-4aed-a3cc-d854cd58063e.pdf (accessed December, 2012).
23. Davidson, T., Husberg, M., Janzon, M., Oldgren, J., and Levin, A.-K. (2013). Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. Eur. Heart J. 34, 177-183.
24. Davies, C., and Abraham, J. (2013). Is there a cure for corporate crime in the drug industry? Effective enforcement of regulations requires more resources and determination to impose robust sanctions. BMJ 346:f755. doi: 10.1136/bmj.f755
25. Davies, N., and Jamali, F. (2004). Cox-II selective inhibitors cardiac toxicity: getting to the heart of the matter. J. Pharm. Pharm. Sci. 7, 332-336.
26. Department of Justice. (2010). Settlement Agreement between United States and AstraZeneca. Available at: http://www.justice.gov/usao/pae/Pharma-Device/astrazeneca_settlementagreement.pdf (accessed January 2013).
27. Dietrich, M., and Horvath, T. (2012). Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat. Rev. Drug Discov. 11, 675-691.
28. DiMasi, J. A., and Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: is biotech different? Manag. Decis. Econ. 28, 469-479.
29. Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., and Dogné, J.-M. (2012). Impact of dabigatran on a large panel of routine or specific coagulation assays - laboratory recommendations for monitoring of dabigatran etexilate. Thromb. Haemost. 107, 985-997.
30. EATG. (2009). 2009 World Pharma Sales Forecast to Top $820 Billion. Available at: http://www.eatg.org/eatg/Global-HIV-News/Pharma-Industry/2009-world-pharma-sales-forecast-to-top-820-billion (accessed December 2012).
31. East Lancashire NHS Medicines Management Health Economy New Medicines and Treatments Group - Dabigatran for prevention of stroke in non-valvular atrial fibrillation (2012). Available at: http://www.elmmb.nhs.uk/formularies/joint-medicines-formulary/2/2-8/ (accessed December, 2012).
32. Eichler, H.-G., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., et al. (2011). Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat. Rev. 10, 495-506.
33. Elton, P., Ratcliffe, J., Fitchet, A., White, A., Sutton, A., and Budden, P. (2011). Re: cost of dabigatran for atrial fibrillation. Rapid response. BMJ. Available at: http://www.bmj.com/content/343/bmj.d6980?tab=responses (accessed December 2012).
34. European Medicines Agency (EMA). (2008). CHMP Assessment Report for Pradaxa (Dabigatran). EMEA/174363/2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000829/WC500041062.pdf (accessed December 2012).
35. European Medicines Agency (EMA). (2009). Withdrawal of the Marketing Authorisation in the European Union. EMEA/39457/2009. Available at: http://www.emea.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500012189.pdf (Accessed December 2012).
36. European Medicines Agency (EMA). (2011). Update on Safety of Pradaxa. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/11/news_detail_001390.jsp&mid=WC0b01ac058004d5c1 (accessed January 2013).
37. European Medicines Agency (EMA). (2012). Pradaxa - Dabigatran. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 (accessed December 2012).
38. EvaluatePharma. (2012). Surveying Tomorrow's BioPharma Landscape. The NASDAQ Biotech Index Up Close. Available at: http://info.evaluatepharma.com/rs/evaluatepharmaltd/http://c431376.r76.cf2.rackcdn.com/43892/fphar-04-00039-HTML/EvaluatePharma_NBI_Up_Close_2012.pdf (accessed January 2013).
39. Fagius, J., Osterman, P. O., Siden, A., and Wiholm, B. E. (1985). Guillain-Barré syndrome following zimelidine treatment. J. Neurol. Neurosurg. Psychiatry 48, 65-69.
40. FDA. (2002). Vioxx (Rofecoxib). Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm154520.htm (accessed January 2013).
41. Federal Agency for Medicines and Health Products (FAMHP). (2011). Dabigatran Etexilate (PRADAXA): Updated Information. Available at: http://www.fagg-afmps.be/en/news/news_dabigatran_pradaxa.jsp?referer=tcm:292-153431-64 (accessed February 2013).
42. Fife Area Drug and Therapeutics Committee. (2012). Area Drug & Therapeutics Bulletin. Prescribing of newer oral anticoagulants. December 2011-March 2012. Available at: http://www.fifeadtc.scot.nhs.uk/bulletins/2012/ADTC%20Bulletin%20Dec-Mar.pdf [accessed December, 2012].
43. Fisk, M., Feeley, J., and Voreacos, D. (2012). J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Available at: http://www.bloomberg.com/news/2012-06-11/j-j-said-to-pay-2-2-billion-to-end-risperdal-sales-probe.html (accessed January 2013).
44. Frank, R. (2007). The ongoing regulation of generic drugs. N. Engl. J. Med. 357, 1993-1996.
45. Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., and Thompson, L. J. (1999). The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281, 1728-1734.
46. Fritz, J., and Cleland, J. (2003). Effectiveness versus efficacy: more than a debate over language. J. Orthop. Sports Phys. Ther. 33, 163-165.
47. Garattini, L., and Casadei, G. (2011). Risk sharing arrangements: what lessons from Italy? Int. J. Technol. Assess 27, 169-172.
48. Garattini, S., Bertele, V., Godman, B., Haycox, A., Wettermark, B., and Gustafsson, L. L. (2008). Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138.
49. Garber, S. T., Sivakumar, W., and Schmidt, R. H. (2012). Neurosurgical complications of direct thrombin inhibitors - catastrophic haemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J. Neurosurg. 116, 1093-1096.
50. Garuoliene, K., Alonderis, T., and Marcinkevicius, M. (2011a). Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth 17, 1-4.
51. Garuoliene, K., Godman, B., Gulbinovic, J., Wettermark, B., and Haycox, A. (2011b). European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11, 341-347.
52. Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., et al. (2001). Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285, 2370-2375.
53. Godman, B. (2011). Risk Sharing Arrangements - Guidance for the Future. Available at: http://www.ceestahc.org/pliki/uoc/20110519/uoc20110519_godman.pdf (accessed December 2012).
54. Godman, B. (2013). Health authority perspective on biosimilars. GaBi J. doi: 10.5639/gabij.2013.0201.010 [Epub ahead of print].
55. Godman, B., Abuelkhair, M., Vitry, A., Abdu, S., Bennie, M., Bishop, I., et al. (2012a). Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBi J. 1, 69-83.
56. Godman, B., Bennie, M., Baumgärtel, C., Sovic Brkicic, L., Burkhardt, T., Fürst, J., et al. (2012b). Essential to increase the use of generics in Europe to maintain comprehensive health care? Farmecon. Health Econ. Ther. Pathw. 13(Suppl. 3), 5-20.
57. Godman, B., Malmstrom, R. E., Bennie, M., Sakshaug, S., Burkhardt, T., Campbell, S., et al. (2012c). Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5-16.
58. Godman, B., Paterson, K., Malmstrom, R., Selke, G., Fagot, J. P., and Mrak, J. (2012d). Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12, 439-441.
59. Godman, B., Wettermark, B., Bennie, M., Diogéne, E., Van Ganse, E., and Gustafsson, L. L. (2012e). Critical role for clinical pharmacologists and hospital pharmacists with enhancing prescribing efficiency for new and existing drugs. (E)Hospital 14, 1-2 (pharma special).
60. Godman, B., Wettermark, B., Bishop, I., Burkhardt, T., Fürst, J., Garuoliene, K., et al. (2012f). European payer initiatives to reduce prescribing costs through use of generics. GaBi J. 1, 22-27.
61. Godman, B., Bucsics, A., Burkhardt, T., Haycox, A., Seyfried, H., and Wieninger, P. (2008). Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8, 357-371.
62. Godman, B., Burkhardt, T., Bucsics, A., Wettermark, B., and Wieninger, P. (2009a). Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid-lowering drugs; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9, 475-484.
63. Godman, B., Schwabe, U., Selke, G., and Wettermark, B. (2009b). Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 435-438.
64. Godman, B., Wettermark, B., Hoffman, M., Andersson, K., Haycox, A., and Gustafsson, L. L. (2009c). Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83.
65. Godman, B., and Gustafsson, L. L. (2013). A new reimbursement systems for innovative pharmaceuticals combining value-based and free market pricing. Appl. Health Econ. Health Policy. 11, 79-82.
66. Godman, B., Sakshaug, S., Berg, C., Wettermark, B., and Haycox, A. (2011a). Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121-129.
67. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2011b). Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.00141
68. Godman, B., Wettermark, B., Bennie, M., Burkhardt, T., and Garuoliene, K. (2011c). Enhancing prescribing efficiency through increased utilisation of generics at low prices. (E)Hospital 13, 28-31.
69. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722.
70. Griffin, D., and Segal, A. (2010). Feds Found Pfizer too Big to Nail. Available at: http://edition.cnn.com/2010/HEALTH/04/02/pfizer.bextra/index.html
71. Gustafsson, L. L., Wettermark, B., Godman, B., Andersén-Karlsson, E., Bergman, U., Hasselström, J., et al. (2011). The "Wise List"- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233.
72. Guthrie, E. (2000). Psychotherapy for patients with complex disorders and chronic symptoms. The need for a new research paradigm. Br. J. Psychiatry 177, 131-137.
73. Haute Authorite de Sante - Commission de la Transparence. (2012). Pradaxa. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-03/pradaxa_15022012_avis_ct10749.pdf (accessed December 2012).
74. Harper, P., Young, L., and Merriman, E. (2012). Bleeding risk with dabigatran in the frail elderly. N. Engl. J. Med. 366, 864-866.
75. Health Improvement Scotland. (2012). Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Available at: www.healthcareimprovementscotland.org/programmes/cardiovascular_disease/dabigatran_consensus_statement.aspx [accessed December, 2012).
76. Heidbüchel, H. T. V., Verhamme, P., Hermans, C., Peeters, A., and Scavée, C. (2011). Practical Guide Dabigatran - Guidance for Use in Particular Situations. Available at: http://www.thrombosisguidelinesgroup.be (accessed December 2012).
77. Hirschler, B. (2012). Fifty Percent off the First Three months of Cancer Medicine. Buy a Course of Eye Treatment and Get Extra Injections Free. A Money-back Guarantee if Your Erectile Dysfunction Pills Don't Work. Available at: http://www.reuters.com/article/2012/10/24/us-pharmaceuticals-europe-pricing-idUSBRE89N0GQ20121024 (accessed January 2013).
78. Holmström, M., Johnsson, H., Lärfars, G., Malmström, R., and Hjemdahl, P. (2009). New drug in atrial fibrillation - how does it function in regular health care? Lakartidningen 106, 3019-3020.
79. Horsley, W. (2010). Dabigatran for the Prevention of Stroke in Patient with Non-valvular Atrial Fibrillation: A Cost Analysis for the NHS North East. NHS North East Treatment Advisory Group. Available at: http://www.netag.nhs.uk/files/appraisal-reports/Dabigatran%20NETAG%20cost%20analysis%20-Jan2010-%20-%20web%20version%202.pdf (accessed December 2012).
80. Huisman, M., Lip, G., Diener, H.-G., Brueckmann, M., van Ryn, J., and Clemens, A. (2012). Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb. Haemost. 107, 838-847.
81. IQWiG. (2010). Merkblatt: Gerinnungshemmende Medikamente sicher anwenden. Available at: http://www.gesundheitsinformation.de/index.624.de.html (accessed January 2013).
82. Institute for Safe Medication Practices. (2011). Quarter Watch 2010 Quarter 4. Available at: http://www.ismp.org/QuarterWatch/pdfs/2010Q4.pdf (accessed December 2012).
83. Interface - A monthly medicines and prescribing bulletin for healthcare professionals in East Lancashire focusing on new therapies. (2011). Available at: www.elmmb.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=48664 (accessed December 2012).
84. Ioannides-Demos, L., Piccenna, L., and McNeil, J. (2011). Pharmacotherapies for obesity: past, current, and future therapies. J. Obes. 2011, 179674.
85. Jack, A. (2008). Balancing Big Pharma's books. BMJ 336, 418-419.
86. Jackevicius, C., Chou, M., Ross, J., Shah, N., and Krumholz, H. (2012). Generic atorvastatin and health care costs. N. Eng. Jn. Med. 366, 201-204.
87. Janusinfo. (2009). Nya riktlinjer & behandlingsstrategier. Rekommendationer avseende antikoagulantiabehandling med warfarin eller dabigatran vid förmaksflimmer. Available at: http://www.janusinfo.se/Documents/Broschyrer/F%C3%B6rskrivarinfo_f%C3%B6rmaksflimmer_A4.pdf (accessed January 2013).
88. Janusinfo. (2012a). Frågor och svar om dabigatran. Available at: http://www.janusinfo.se/Documents/Expertgruppsdokument/dabigatran_fragor_svar_120208.pdf (accessed January 2013).
89. Janusinfo. (2012b). Välj i första hand warfarin som tromboemboliprofylax vid förmaksflimmer. Följ riktlinjer för warfarinbehandling. Available at: http://www.janusinfo.se/Global/Kloka%20Rad/warfarin_120320.pdf (accessed January 2013).
90. Jaroslawski, S., and Toumi, M. (2011). Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv. Res. 11:259. doi: 10.1186/1472-6963-11-259
91. Jommi, C. (2012). Managed Market Entry for Drugs in Italy. EMAUD Market Access Newsletter. Available at: http://www.slideshare.net/Mondher_Toumi/market-access-newsletter-emaud-june2012 (accessed December 2012).
92. Joppi, R., Cinconze, E., Mezzalira, M., Pase, D., Poggiani, C., Rossi, E., et al. (2013). Hospitalized patients with atrial fibrillation compared to those included in recent trials on novel oral anticoagulants: A population-based study. Eur. J. Intern. Med. doi: 10.1016/j.ejim.2013.02.018 [Epub ahead of print].
93. Kaiser, J. (2012). New cystic fibrosis drug offers hope, at a price. Science 335, 645.
94. Kalaba, M., Godman, B., Vuksanovic, A., Bennie, M., and Malmstrom, R. E. (2012). Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? J. Comp. Eff. Res. 1, 539-549.
95. Kansal, A. R., Sorensen, S. V., Gani, R., Robinson, P., Pan, F., Plumb, J. M., et al. (2012). Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98, 573-578.
96. Kappos, L., Bates, D., and Edan, G. (2011). Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 10, 745-758.
97. Keegan, B. (2011). Natalizumab for multiple sclerosis: a complicated treatment. Lancet Neurol. 10, 677-678.
98. Keele University School of Pharmacy. (2012). Medicines Management - Effective Shared Care Agreement Toolkit - Dabigatran. Available at: http://www.esca-keele.co.uk/dabigatran/ (accessed January 2013).
99. Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H. C., et al. (2007). Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur. Heart J. 28, 2803-2817.
100. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., Johnson, B. T., et al. (2008). Initial severity and antidepressant benefits: a meta analysis of data submitted to the Food and Drug Administration. PLoS Med. 5:e45. doi: 10.1371/journal.pmed.0050045
101. Klemp, M., and Frønsdal, K. (2011). What principles should govern the use of managed entry agreements? Int. J. Technol. Assess. Health Care 27, 77-83.
102. Kmietowicz, Z. (2013). GSK backs campaign for disclosure of trial data. BMJ 346, f819.
103. Kolasa, K., Schubert, S., Manca, A., and Hermanowski, T. (2011). A review of Health Technology Assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy 102, 145-151.
104. Kreatinin-Clearance Rechner (Creatinine Clearance calculator). (2013). Cocktroft-Gault Formula. Available at: http://www.dialyse-hamburg.de/kreacal.htm (accessed January 2013).
105. KVH - Aktuell. (2010). Informationsdienst der Kassenärztlichen Vereinigung Hessen Pharmakotherapie. Available at: http://www.kvberlin.de/40presse/50publikation/20pharmakotherapie/2010/pharmakotherapie_1001.pdf (accessed December 2012).
106. Legrand, M., Mateo, J., Aibaud, A., Ginisty, S., Eftekhari, P., Huy, P. T., et al. (2011). The use of dabigatran in elderly patients. Arch. Intern. Med. 8, 432-439.
107. Lexchin, J., and Kohler, J. (2011). The danger of imperfect regulation: OxyContin use in the United States and Canada. Int. J. Risk Saf. Med. 23, 233-240.
108. Liesenfeld, K. H., Lehr, T., Dansirikul, C., Reilly, P. A., Connolly, S. J., Ezekowitz, M. D., et al. (2011). Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost. 9, 2168-2175.
109. Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., et al. (2004). Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110, 1042-1046.
110. Lothian Prescribing Bulletin. (2012) Oral anticoagulants - what's new? Available at: http://www.ljf.scot.nhs.uk/PrescribingBulletins/Prescribing%20Bulletins/Lothian%20Prescribing%20Bulletin%20Issue%2055%20May%202012%20FINAL.pdf (accessed December 2012).
111. Luengo-Fernandez, R., Gray, A. M., and Rothwell, P. M. (2006). Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke 37, 2579-2587.
112. Malmström, R. E. (2009). "New anticoagulants," in Essential Guide to Blood Coagulation, eds J. P. Antovic and M. Blombäck (Oxford: Wiley-Blackwell Publishing), 91-102.
113. Mannuci, M., Nobil, A., and Garattini, S. (2012). New drugs for thromboprophylaxis in atrial fibrillation. Eur. J. Intern. Med. 23, 1-5.
114. Markovic-Pekovic, V., Škrbic, R., Godman, B., and Gustafsson, L. L. (2012). Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency; influence and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 5, 661-671.
115. Marshall, S., Fearon, P., Dawson, J., and Quinn, T. (2013). Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review. Expert Rev. Pharmacoecon. Outcomes Res. 13, 29-42.
116. Martikainen, J., Saastamoinen, L., Korhonen, M., Enlund H., and Helin-Salmivaara, A. (2010). Impact of restricted reimbursement on the use of statins in Finland. Med. Care 48, 761-766.
117. Martin, D. (2012). Drug Firms are 'Risking Lives by Hiding Bad Trials and Side Effects of Their Medicines'. Available at: http://www.dailymail.co.uk/news/article-2222220/Drug-firms-risking-lives-hiding-bad-trials-effects-medicines.html?ito=feeds-newsxml) (accessed November 12, 2012).
118. McGinn, D., Godman, B., Lonsdale, J., Way, R., Wettermark, B., and Haycox, A. (2010). Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73-85.
119. Medicine Balance (MEDICIJNBALANS). (2012). Oral Anticoagulants. Available at: http://www.medicijnbalans.nl/medicijngroepen/orale-anticoagulantia (accessed December 2012).
120. Medicin & Läkemedel. (2012). E n t i d N I N G f r å n S t o c k h o l m s l ä n s l ä k e m e d e l s k o mm i t t é h ä l s o - o c h s j u k v å r d s f ö r va l t n i n g e n. Frågor & svar om dabigatran Expertråden ger svar på frågor om nytt antikoagulantium. Available at: http://www.janusinfo.se/publikationer/evidens/nr01/files/assets/seo/page1.html (accessed December 2012).
121. Melander, H., Ahlqvist-Rastad, J., Meijer, G., and Beermann, B. (2003). Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326, 1171-1173.
122. Mello, M. M., Abiola, S., and Colgrove, J. (2012). Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination. Am. J. Public Health. 102, 893-898.
123. Merck. (2002). Important Prescribing Information. Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM171089.pdf (accessed January 2013).
124. Merck. (2004). Merck Announces Voluntary Worldwide Withdrawal of VIOXX®. Available at: http://www.pbm.va.gov/vioxx/Dear%20Healthcare%20Professional.pdf (accessed January 2013).
125. MHRA UK. (2004). Immediate With-drawal of Rofecoxib (Vioxx/Vioxxacutate). Available at: http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON1004263 (accessed January 2013).
126. Midlands Therapeutic Review and Advisory Committee (MTRAC). (2012). COMMISSIONING GUIDANCE Dabigatran Etexilate for Stroke Prevention in Patients with Atrial Fibrillation. Available at: http://www.keele.ac.uk/media/keeleuniversity/fachealth/fachealthsop/mtrac/documents/summary/Dabigatran%20VS%2012.pdf (accessed December 2012).
127. Mismetti, P., and Laporte, S. (2010). New oral antithrombotics: a need for laboratory monitoring. J. Thromb. Haemost. 8, 621-626.
128. Moreira, F., Alexandre, J., and Crippa, S. (2009). The psychiatric side-effects of rimonabant. Rev. Bras. Psiquiatr. 31, 145-153.
129. Mullard, A. (2012). 2011 FDA drug approvals. Nat. Rev. Drug Discov. 11, 91-94.
130. Nagle, P. C., Nicita, C. A., Gerdes, L. A., and Schmeichel, C. J. (2008). Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am. J. Manag. Care 14, 226-229.
131. National Cancer Institute. (2010). Surveillance Epidemiology and End Results (SEER). Washington, DC: National Cancer Institute [online]. Available at: http://seer.cancer.gov/ (accessed December 2012).
132. National Centre for Pharmacoeconomics. (2011). Dabigatran Etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation. Available at: http://www.ncpe.ie/drugs/dabigatran-etexilate-pradaxa-for-the-prevention-of-stroke-and-systematic-embolisom-in-atrial-fibrillation/ (accessed December 2012).
133. National Institute for Health and Clinical Excellence. (2012). Dabigatran Etexilate for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation. NICE Technology Appraisal Guidance 249. Available at: http://www.nice.org.uk/nicemedia/live/13677/58470/58470.pdf (accessed December 2012).
134. Neue Arzneimittel. (2011). Information der Arzneimittelkommission der deutschen ärzteschaft (Akdä) Pradaxa® (Dabigatran) - neu zugelassene Indikation. Available at: http://www.akdae.de/Arzneimitteltherapie/NA/Archiv/2011030-Pradaxa.pdf (accessed December 2012).
135. NHS Cumbria, NHS Lancashire. (2012a). Consensus statement: Oral anti-coagulant drugs for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Available at: http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/NOAC-Consensus-Statement.pdf (Accessed December 2012).
136. NHS Cumbria, NHS Lancashire. (2012b). Guidance for prescribing of dabigatran in patients with non-valvular AF. Available at: http://www.cumbria.nhs.uk/ProfessionalZone/MedicinesManagement/Guidelines/Prescribing-Guidance-for-NOACs.pdf (accessed December, 2012).
137. NHS Highland - The Pink One. (2012). Dabigatran recommended for specific patient groups. December 2011 to January 2012. Available at: http://www.nhshighland.scot.nhs.uk/Publications/Documents/Newsletters/Pharmacy/The%20Pink%20One%20No%2095%20December%202011%20-%20January%202012.pdf (accessed December, 2012).
138. NHS Improvement. Guidance on Risk Assessment and Stroke Prevention for Atrial Fibrillation (GRASP - AF). (2013). Available at: http://www.improvement.nhs.uk/graspaf/ (accessed February 2013).
139. NHS Tayside. (2011). Dabigatran, Tayside Prescriber Supplement No. 112. December 2011. Available at: http://www.nhstaysideadtc.scot.nhs.uk/approved/bulletin/adtcsupp/2011/No%20112.pdf (accessed December 2012).
140. NPS MEDICINEWISE. (2012). Delay in PBS Listing of Dabigatran. Available at: http://www.nps.org.au/publications/health-professional/nps-direct/2012/delay-in-PBS-listing?utm_source=nps-direct&utm_medium=email&utm_campaign=issue-3-2013 (accessed January 2013).
141. Oral anticoagulants. (2012). What's new? LOTHIAN PRESCRIBING BULLETIN. Issue 65, May 2012. Available at: http://www.ljf.scot.nhs.uk/PrescribingBulletins/Prescribing%20Bulletins/Lothian%20Prescribing%20Bulletin%20Issue%2055%20May%202012%20FINAL.pdf [accessed December 2012].
142. Ostazen 2011. Consensus statement on Dabigatran - Sociedad Vasco Navarra de Cardiología, Sociedad Vasca de Medicina de Familia y Comunitaria (OSATZEN), Sociedad de Neurología del País Vasco, Asociación del Norte de Hematología-Hemoterapia, Sociedad de Medicina Interna País Vasco, Sociedad Vasca de Farmacia Hospitalaria, y la vocalía de Euskadi de la Sociedad Española de Farmacéuticos de Atención Primaria 2011. (2011). Available at: http://www.osakidetza.euskadi.net/r85-pkcevi02/es/contenidos/informacion/cevime_atencion_primaria/es_cevime/r01hRedirectCont/contenidos/informacion/cevime_nuevo_medicamento/es_nme/adjuntos/Consenso_dabigatran_c_bis.pdf (accessed December, 2012).
143. O'Shaughnessy. (2009). Adieu Rimoabant. Available at: http://www.beyondthc.com/wp-content/uploads/2012/05/2009AdieuRimonabant.pdf (accessed December 2012).
144. Östergötland. (2012). Strukturerat införande av nya antikoagulantia i östergötland - Dabigatran - 111011. Available at: http://www.lio.se/pages/142057/Baseline-formulär%20och%20checklista%20Dabigatran%205%20111011.pdf (accessed December 2012).
145. Ozieranski, P., McKee, M., and King, L. (2012). Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? Health Econ. Policy Law 7, 175-195.
146. Papeix, C., Vukusic, S., Passante, N., Ionescu, I., Frangoulis, B., Stankoff, S., et al. (2012). Natalizumab Discontinuation in Clinical Practice: A Systematic Observational Study from the National TYSEDMUS Cohort of Multiple Sclerosis Patients Treated with Natalizumab in France. Available at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=137397&XNSPRACHE_ID=2&XNKONGRESS_ID=150&XNMASKEN_ID=900 (accessed December 2012).
147. Persson, U., Svensson, J., and Pettersson, B. (2012). A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl. Health Econ. Health Policy 10, 217-225.
148. Pink, J., Lane, S., Pirmohamed, M., Dyfrig, A., and Hughes, D. (2011). Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ 343, d6333.
149. Reicin, A., Barr, E., and Shapiro, D. (2001). Cardiovascular safety profile of rofecoxib: a meta-analysis. Arthritis Rheum. 44, S372;S230;S266.
150. Rodriguez, R., Carrier, M., and Wells, P. (2013). Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? Int. Soc. Thromb. Haem. 11, 390-394.
151. Rolfe, S., Papadopoulos, S., and Cabral, K. P. (2010). Controversies of anticoagulation reversal in life-threatening bleeds. J. Pharm. Pract. 23, 217-225.
152. Scottish Medicines Consortium. (2011). Dabigatran Etexilate 110 mg and 150 mg Hard Capsules (Pradaxa®) SMC No. (672/11). Available at: http://www.scottishmedicines.org.uk/files/advice/dabigatran_Pradaxa_FINAL_August_2011_Amended_05.09.11_for_website.pdf (accessed December 2012).
153. Selyukh, A. (2011). Seattle Genetics Cancer Drug Price May Top $100,000. Available at: http://www.reuters.com/article/2011/08/22/us-seattlegenetics-idUSTRE77L5EB20110822 (accessed February 2013).
154. Sermet, C., Andrieu, V., Godman, B., Van Ganse, E., Haycox, A., and Reynier, J. P. (2010). Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7-24.
155. Shuchman, M. (2006). Delaying generic competition - corporate payoffs and the future of Plavix. N. Engl. J. Med. 355, 1297-1300.
156. Siviero, P., Sammarco, A., Tafuri, G., and Pani, L. (2012). An HTA approach for pricing and reimbursement decisions: the Italian experience with managed entry agreements. Gac. Sanit. 26, 280.
157. Southworth, M., Reichman, M., and Unger, E. (2013). Dabigatran and postmarketing reports of bleeding. N. Engl. J. Med. doi: 10.1056/NEJMp1302834 [Epub ahead of print].
158. Stangier, J., and Clemens, A. (2009). Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost. 15(Suppl. 1), 9S-16S.
159. Stangier, J., Stahle, H., Rathgen, K., and Fuhr, R. (2008). Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47, 47-59.
160. Stewart, S., Hart, C. L., Hole, D. J., and McMurray, J. J. (2001). Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 86, 516-521.
161. Stewart, S., Murphy, N., Walker, A., McGuire, A., and McMurray, J. J. (2004). Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 90, 286-292.
162. Stockholms läns landsting. (2011). Prognos över användning och kostnader för läkemedel i SLL 2011-2012. Available at: http://www.janusinfo.se/Documents/Lakemedelsstatistik/Prognos%202011_2012_110420%20final.pdf (accessed January 2013).
163. Stollberger, C., and Finsterer, J. (2013). Concerns about storage and application of dabigatran and rivaroxaban. Eur. J. Clin. Pharmacol. 69, 739-740.
164. Sullivan, R., Peppercorn, P., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., et al. (2011). Delivering affordable cancer care in high-income countries. Lancet Oncol. 12, 933-980.
165. Swedish Council on Health Technology Assessment. (2011) Dabigatran för att förebygga stroke vid förmaksflimmer. Stockholm: Statens beredning för medicinsk utvärdering (SBU). SBU Alert-rapport nr 2011-04. Available at: http://www.sbu.se; in English: http://www.sbu.se/en/Published/Alert/Dabigatran-to-Prevent-Stroke-in-Patients-With-Atrial-Fibrillation/ (accessed December 2012).
166. Taylor, L. (2011). Australian Govt Blocks Subsidies for New Drugs. Available at: http://www.pharmatimes.com/Article/11-03-15/Australian_govt_blocks_subsidies_for_new_drugs.aspx (accessed December 2012).
167. Ten Cate, H. (2012). Monitoring new oral anticoagulants, managing thrombosis, or both? Thromb. Haemost. 107, 803-805.
168. Therapie Tipps. (2012). Wiener Gebietskrankenkasse p. 23 Issue 2. Available at: http://www.wgkk.at/mediaDB/874712_therapietipps_sb_2_2012.pdf (accessed December 2012).
169. Thompson, A. (2010). NDA 22-512 Dabigatran - Efficacy Review. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226704.pdf?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=dabigatran&utm_content=10 (accessed December 2012).
170. UK Medicines Information. (2012). New Drugs Online Report for Vemurafenib. Available at: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5009 (accessed December 2012).
171. UKMi Medicines Information. (2013). New Drugs Online Report for Crizotinib. Available at: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5097 (accessed February 2013).
172. van Woerkom, M., Piepenbrink, J. F., Godman, B., Metz, J., Campbell, S., Bennie, M., et al. (2012). Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J. Comp. Eff. Res. 1, 527-538.
173. Vogler, S., Zimmermann, N., Habl, C., Piessnegger, J., and Bucsics, A. (2012). Discounts and rebates granted to public payers for medicines in European countries. South Med. Rev. 5, 38-46.
174. Voncina, L., and Strizrep, T. (2011). Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth 16, 20-22.
175. Voncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479.
176. Weir, M. R., Sperling, R. S., Reicin, A., and Gertz, B. J. (2003). Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am. Heart J. 146, 591-604.
177. Wells, K. B. (1999). Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am. J. Psychiatry 156, 5-10.
178. Wettermark, B., Godman, B., Andersson, K., Gustafsson, L. L., Haycox, A., and Bertele, V. (2008). Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550.
179. Wettermark, B., Godman, B., Eriksson, C., van Ganse, E., Garattini, S., Joppi, R., et al. (2010a). Einführung neuer Arzneimittel in europäische Gesundheitssysteme. GGW 10, 24-34. (Introduction of new medicines into European healthcare systems).
180. Wettermark, B., Godman, B., Neovius, M., Hedberg, N., Mellgren, T. O., and Kahan, T. (2010b). Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229.
181. Wettermark, B., Persson, M., Wilking, N., Kalin, M., Korkmaz, S., Hjemdahl, P., et al. (2010c). Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Ser. Res. 10:128. doi: 10.1186/1472-6963-10-128
182. Wettermark, B., Godman, B., Jacobsson, B., and Haaijer-Ruskamp, F. (2009a). Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137-147.
183. Wettermark, B., Pehrsson, A., Juhasz-Haverinen, M., Veg, A., Edlert, M., Törnwall-Bergendahl, G., et al. (2009b). Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189.
184. Wong, D., Sullivan, K., and Heap, G. (2012). The pharmaceutical market for obesity therapies. Nat. Rev. Drug Discov. 11, 669-670.
185. Wood, S. (2011). Deaths Prompt Dabigatran Safety Advisory in Japan. Available at: http://www.theheart.org/article/1264365.do (accessed December 2012).
186. World Health Organisation (WHO). (2009). Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.whocc.no (accessed December 2012).
187. Yukhananov, A. (2011). Reuters. Available at: http://www.reuters.com/article/2011/08/26/fda-pfizer-idUSN1E77P1UG20110826 (accessed December 2012).